Vogt ‐Koyanagi‐Harada disease in pregnancy: Case report and review of 32 patients in the literature
Retinal cross-sectional images of optical coherence tomography at the initial visit (A, B), a week later (C, D), 3 week later (E, F), and 4 weeks later (G, H) from the initial visit. Images in the right eye are in the left column (A, C, E, and G) and images in the left eye are in the right column (B, D, F, and H). Each panel with alphabetical labelling shows color photograph (top left), red-free photograph (bottom left), horizontal section of the image from the nasal to the temporal side (top right), and vertical section of the image from the superior to the inferior side (bottom right). Note sequential decrease of su...
Source: Clinical Case Reports - March 12, 2024 Category: General Medicine Authors: Toshihiko Matsuo,
Kasumi Takahashi,
Tsunemasa Kondo Tags: CASE REPORT Source Type: research
Eculizumab use throughout pregnancy in two patients with aquaporin ‐4‐positive neuromyelitis optica spectrum disorder
ConclusionsWe present two cases of pregnant women with AQP4+ NMOSD treated with eculizumab. Both women gave birth to healthy babies, have had no relapses since initiating eculizumab, and continued their treatment after birth. These cases are further evidence of the successful use of eculizumab during pregnancy. (Source: Clinical and Experimental Neuroimmunology)
Source: Clinical and Experimental Neuroimmunology - March 12, 2024 Category: Neurology Authors: Takeshi Fujimoto,
Yasuhiro Maeda Tags: CASE REPORT Source Type: research
A placebo-controlled, double-blind study evaluating the effect of orally administered polyunsaturated fatty acids on the oclacitinib dose for atopic dogs
CONCLUSION: Oral supplementation of PUFA allowed dose reduction of oclacitinib and improved PVAS, QoL, QoC and GA. The use of PUFA is recommended and was safe in the atopic study dogs receiving oclacitinib.PMID:38465482 | DOI:10.1111/vde.13246 (Source: Veterinary Dermatology)
Source: Veterinary Dermatology - March 11, 2024 Category: Veterinary Research Authors: Laura Sch äfer Nina Thom Source Type: research
Recurrent Tolosa-Hunt syndrome: a case report
CONCLUSION: Tolosa-Hunt syndrome is a syndrome of painful ophthalmoplegia which responds well to steroid therapy but has a tendency to recur. Hence, patients must be adequately informed about the reoccurrence and kept under follow-up.PMID:38463132 | PMC:PMC10923349 | DOI:10.1097/MS9.0000000000001745 (Source: Annals of Medicine)
Source: Annals of Medicine - March 11, 2024 Category: Internal Medicine Authors: Shashank Neupane Prasamsa Pudasaini Bishal Dhakal Pasang Sherpa Pooja Rokaya Anukul Subedi Source Type: research
A placebo-controlled, double-blind study evaluating the effect of orally administered polyunsaturated fatty acids on the oclacitinib dose for atopic dogs
CONCLUSION: Oral supplementation of PUFA allowed dose reduction of oclacitinib and improved PVAS, QoL, QoC and GA. The use of PUFA is recommended and was safe in the atopic study dogs receiving oclacitinib.PMID:38465482 | DOI:10.1111/vde.13246 (Source: Veterinary Dermatology)
Source: Veterinary Dermatology - March 11, 2024 Category: Veterinary Research Authors: Laura Sch äfer Nina Thom Source Type: research
Recurrent Tolosa-Hunt syndrome: a case report
CONCLUSION: Tolosa-Hunt syndrome is a syndrome of painful ophthalmoplegia which responds well to steroid therapy but has a tendency to recur. Hence, patients must be adequately informed about the reoccurrence and kept under follow-up.PMID:38463132 | PMC:PMC10923349 | DOI:10.1097/MS9.0000000000001745 (Source: Annals of Medicine)
Source: Annals of Medicine - March 11, 2024 Category: Internal Medicine Authors: Shashank Neupane Prasamsa Pudasaini Bishal Dhakal Pasang Sherpa Pooja Rokaya Anukul Subedi Source Type: research
A placebo-controlled, double-blind study evaluating the effect of orally administered polyunsaturated fatty acids on the oclacitinib dose for atopic dogs
CONCLUSION: Oral supplementation of PUFA allowed dose reduction of oclacitinib and improved PVAS, QoL, QoC and GA. The use of PUFA is recommended and was safe in the atopic study dogs receiving oclacitinib.PMID:38465482 | DOI:10.1111/vde.13246 (Source: Veterinary Dermatology)
Source: Veterinary Dermatology - March 11, 2024 Category: Veterinary Research Authors: Laura Sch äfer Nina Thom Source Type: research
A placebo-controlled, double-blind study evaluating the effect of orally administered polyunsaturated fatty acids on the oclacitinib dose for atopic dogs
CONCLUSION: Oral supplementation of PUFA allowed dose reduction of oclacitinib and improved PVAS, QoL, QoC and GA. The use of PUFA is recommended and was safe in the atopic study dogs receiving oclacitinib.PMID:38465482 | DOI:10.1111/vde.13246 (Source: Veterinary Dermatology)
Source: Veterinary Dermatology - March 11, 2024 Category: Veterinary Research Authors: Laura Sch äfer Nina Thom Source Type: research
A placebo-controlled, double-blind study evaluating the effect of orally administered polyunsaturated fatty acids on the oclacitinib dose for atopic dogs
CONCLUSION: Oral supplementation of PUFA allowed dose reduction of oclacitinib and improved PVAS, QoL, QoC and GA. The use of PUFA is recommended and was safe in the atopic study dogs receiving oclacitinib.PMID:38465482 | DOI:10.1111/vde.13246 (Source: Veterinary Dermatology)
Source: Veterinary Dermatology - March 11, 2024 Category: Veterinary Research Authors: Laura Sch äfer Nina Thom Source Type: research
A placebo-controlled, double-blind study evaluating the effect of orally administered polyunsaturated fatty acids on the oclacitinib dose for atopic dogs
CONCLUSION: Oral supplementation of PUFA allowed dose reduction of oclacitinib and improved PVAS, QoL, QoC and GA. The use of PUFA is recommended and was safe in the atopic study dogs receiving oclacitinib.PMID:38465482 | DOI:10.1111/vde.13246 (Source: Veterinary Dermatology)
Source: Veterinary Dermatology - March 11, 2024 Category: Veterinary Research Authors: Laura Sch äfer Nina Thom Source Type: research
A placebo-controlled, double-blind study evaluating the effect of orally administered polyunsaturated fatty acids on the oclacitinib dose for atopic dogs
CONCLUSION: Oral supplementation of PUFA allowed dose reduction of oclacitinib and improved PVAS, QoL, QoC and GA. The use of PUFA is recommended and was safe in the atopic study dogs receiving oclacitinib.PMID:38465482 | DOI:10.1111/vde.13246 (Source: Veterinary Dermatology)
Source: Veterinary Dermatology - March 11, 2024 Category: Veterinary Research Authors: Laura Sch äfer Nina Thom Source Type: research
A placebo-controlled, double-blind study evaluating the effect of orally administered polyunsaturated fatty acids on the oclacitinib dose for atopic dogs
CONCLUSION: Oral supplementation of PUFA allowed dose reduction of oclacitinib and improved PVAS, QoL, QoC and GA. The use of PUFA is recommended and was safe in the atopic study dogs receiving oclacitinib.PMID:38465482 | DOI:10.1111/vde.13246 (Source: Veterinary Dermatology)
Source: Veterinary Dermatology - March 11, 2024 Category: Veterinary Research Authors: Laura Sch äfer Nina Thom Source Type: research
A placebo-controlled, double-blind study evaluating the effect of orally administered polyunsaturated fatty acids on the oclacitinib dose for atopic dogs
CONCLUSION: Oral supplementation of PUFA allowed dose reduction of oclacitinib and improved PVAS, QoL, QoC and GA. The use of PUFA is recommended and was safe in the atopic study dogs receiving oclacitinib.PMID:38465482 | DOI:10.1111/vde.13246 (Source: Veterinary Dermatology)
Source: Veterinary Dermatology - March 11, 2024 Category: Veterinary Research Authors: Laura Sch äfer Nina Thom Source Type: research
A placebo-controlled, double-blind study evaluating the effect of orally administered polyunsaturated fatty acids on the oclacitinib dose for atopic dogs
CONCLUSION: Oral supplementation of PUFA allowed dose reduction of oclacitinib and improved PVAS, QoL, QoC and GA. The use of PUFA is recommended and was safe in the atopic study dogs receiving oclacitinib.PMID:38465482 | DOI:10.1111/vde.13246 (Source: Veterinary Dermatology)
Source: Veterinary Dermatology - March 11, 2024 Category: Veterinary Research Authors: Laura Sch äfer Nina Thom Source Type: research
A placebo-controlled, double-blind study evaluating the effect of orally administered polyunsaturated fatty acids on the oclacitinib dose for atopic dogs
CONCLUSION: Oral supplementation of PUFA allowed dose reduction of oclacitinib and improved PVAS, QoL, QoC and GA. The use of PUFA is recommended and was safe in the atopic study dogs receiving oclacitinib.PMID:38465482 | DOI:10.1111/vde.13246 (Source: Veterinary Dermatology)
Source: Veterinary Dermatology - March 11, 2024 Category: Veterinary Research Authors: Laura Sch äfer Nina Thom Source Type: research
